Therapeutic Sequences in the Treatment of High-Risk Prostate Cancer: Paving the Way Towards Multimodal Tailored Approaches

Various definitions are currently in use to describe high-risk prostate cancer. This variety in definitions is important for patient counseling, since predicted outcomes depend on which classification is applied to identify patient’s prostate cancer risk category. Historically, strategies for the tr...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in oncology 2021-08, Vol.11, p.732766-732766
Main Authors: Marvaso, Giulia, Corrao, Giulia, Zaffaroni, Mattia, Pepa, Matteo, Augugliaro, Matteo, Volpe, Stefania, Musi, Gennaro, Luzzago, Stefano, Mistretta, Francesco Alessandro, Verri, Elena, Cossu Rocca, Maria, Ferro, Matteo, Petralia, Giuseppe, Nolè, Franco, De Cobelli, Ottavio, Orecchia, Roberto, Jereczek-Fossa, Barbara Alicja
Format: Article
Language:English
Subjects:
hadrontherapy
high risk prostate cancer
iPARP treatment
narrative review
Oncology
personalized medicine
second-generation antiandrogens
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Various definitions are currently in use to describe high-risk prostate cancer. This variety in definitions is important for patient counseling, since predicted outcomes depend on which classification is applied to identify patient’s prostate cancer risk category. Historically, strategies for the treatment of localized high-risk prostate cancer comprise local approaches such as surgery and radiotherapy, as well as systemic approaches such as hormonal therapy. Nevertheless, since high-risk prostate cancer patients remain the group with higher-risk of treatment failure and mortality rates, nowadays, novel treatment strategies, comprising hypofractionated-radiotherapy, second-generation antiandrogens, and hadrontherapy, are being explored in order to improve their long-term oncological outcomes. This narrative review aims to report the current management of high-risk prostate cancer and to explore the future perspectives in this clinical setting.
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2021.732766